Mercadon locks out TRACEr technology to develop next-generation T-cell therapy

The effective dose of TCE is more than 10,000 times lower than that of typical antibodies, but TCE also has some limitations, such as dose-limiting toxicity, poor pharmacodynamic properties and reduced efficacy.
, systemic immunoactivation is a major obstacle to the development of TCE therapy.
The first generation of TCE triggers a systemic immune response that attacks not only tumors, but also healthy tissue, which can be life-threatening, and second generation TCE reduces the initial systemic immune response, but over time, the accumulation of activated TCE in the body leads to immune activation in healthy tissue.
not only limits the development of TCE, but also reduces the dose of drugs that can be used safely.
In response to these limitations, Janux developed tumor-activated T Cell Engager (TRACTr) technology, which combines cross-pharmacological dynamics with tumor-specific activation to enable the drug to actively accumulate in tumors and prevent the drug from accumulating in healthy tissues.
preclinical studies have shown that TRACTr drugs can achieve high safety multiples and have anti-tumor properties comparable to standard TCE, while preventing cytokine release, healthy tissue toxicity, and systemic immunoactivation.
source: Janux's official website, TCE, has a prominent effect in blood cancers, and although TCE for solid tumors is not yet approved, about one-third of ongoing clinical trials worldwide are targeted at solid tumors, similar in proportion to CAR-T.
Janux pipeline also has a number of drugs being developed that target solid tumors, including colorectal, gastroesophageal, prostate, non-small cell lung, triple-negative breast and ovarian cancer.
" partnership with Mercator provides us with important expertise and resources to develop the next generation of T-cell ligator therapy, which is expected to enable immunotherapy to serve more cancer patients.
," said Dr. David Campbell, President and CEO of Janux.
。